Anti-CCL2/ GDCF-2/ HC11 functional antibody

Anti-CCL2/ GDCF-2/ HC11 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to CCL2/CCL2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T11309-Ab-1/ GM-Tg-hg-T11309-Ab-2Anti-Human CCL2 monoclonal antibodyHuman
GM-Tg-rg-T11309-Ab-1/ GM-Tg-rg-T11309-Ab-2Anti-Rat CCL2 monoclonal antibodyRat
GM-Tg-mg-T11309-Ab-1/ GM-Tg-mg-T11309-Ab-2Anti-Mouse CCL2 monoclonal antibodyMouse
GM-Tg-cynog-T11309-Ab-1/ GM-Tg-cynog-T11309-Ab-2Anti-Cynomolgus/ Rhesus macaque CCL2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T11309-Ab-1/ GM-Tg-felg-T11309-Ab-2Anti-Feline CCL2 monoclonal antibodyFeline
GM-Tg-cang-T11309-Ab-1/ GM-Tg-cang-T11309-Ab-2Anti-Canine CCL2 monoclonal antibodyCanine
GM-Tg-bovg-T11309-Ab-1/ GM-Tg-bovg-T11309-Ab-2Anti-Bovine CCL2 monoclonal antibodyBovine
GM-Tg-equg-T11309-Ab-1/ GM-Tg-equg-T11309-Ab-2Anti-Equine CCL2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T11309-Ab-1/ GM-Tg-hg-T11309-Ab-2; GM-Tg-rg-T11309-Ab-1/ GM-Tg-rg-T11309-Ab-2;
GM-Tg-mg-T11309-Ab-1/ GM-Tg-mg-T11309-Ab-2; GM-Tg-cynog-T11309-Ab-1/ GM-Tg-cynog-T11309-Ab-2;
GM-Tg-felg-T11309-Ab-1/ GM-Tg-felg-T11309-Ab-2; GM-Tg-cang-T11309-Ab-1/ GM-Tg-cang-T11309-Ab-2;
GM-Tg-bovg-T11309-Ab-1/ GM-Tg-bovg-T11309-Ab-2; GM-Tg-equg-T11309-Ab-1/ GM-Tg-equg-T11309-Ab-2
Products NameAnti-CCL2 monoclonal antibody
Formatmab
Target NameCCL2
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CCL2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-094Pre-Made Carlumab biosimilar, Whole mAb, Anti-CCL2 Antibody: Anti-HC11/MCAF/MCP1/MCP-1/SCYA2/GDCF-2/SMC-CF/HSMCR30 therapeutic antibody
    Target AntigenGM-Tg-g-T11309-Ag-1Recombinant multi-species CCL2/ GDCF-2/ HC11 protein
    CytokineGM-Tg-g-T11309-Ag-1chemokine (C-C motif) ligand 2 (CCL2) protein
    ORF Viral VectorpGMAP000030Human CCL2 Adenovirus plasmid
    ORF Viral VectorvGMAP000030Human CCL2 Adenovirus particle
    ORF Viral VectorpGMLP000392human CCL2 Lentivirus plasmid
    ORF Viral VectorvGMLP000392human CCL2 Lentivirus particle
    ORF Viral VectorpGMLPm000042mouse Ccl2 Lentivirus plasmid
    ORF Viral VectorvGMLPm000042mouse Ccl2 Lentivirus particle
    ORF Viral VectorpGMLPm003496mouse Ccl12 Lentivirus plasmid
    ORF Viral VectorvGMLPm003496mouse Ccl12 Lentivirus particle


    Target information

    Target IDGM-T11309
    Target NameCCL2
    Gene ID6347,20296,574138
    Gene Symbol and SynonymsCCL2,GDCF-2,HC11,HSMCR30,JE,MCAF,MCP-1,MCP1,SCYA2,Sigje,SMC-CF
    Uniprot AccessionP13500,P61275
    Uniprot Entry NameCCL2_HUMAN,CCL2_MACMU
    Protein Sub-locationSecreted Protein/Potential Cytokines
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseBreast Cancer, Systemic lupus erythematosus (SLE), Idiopathic hypoparathyroidism, IgA glomerulonephritis, Lupus Glomerulonephritis, Nephrotic syndrome, Nephrotic syndrome with focal and segmental glomerular lesions, Overactive bladder, Proteinuria, Renal fibrosis, Schistosomiasis, Tubulo-interstitial nephropathy in systemic lupus erythematosus, Urolithiasis, Vasculitis, Autosomal Dominant Polycystic Kidney Disease, Bacterial sepsis of newborn, Chronic Kidney Disease, Congenital hydronephrosis, Congenital occlusion of ureteropelvic junction, Diabetic Nephropathy, Glomerulonephritis, Hepatic fibrosis, Hydronephrosis with renal and ureteral calculous obstruction, Hypertension, Type 2 diabetes mellitus with diabetic nephropathy, breast cancer
    Gene EnsemblENSG00000108691
    Target ClassificationCheckpoint-Immuno Oncology

    The target: CCL2, gene name: CCL2, also named as GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1, SCYA2, SMC-CF. This gene is one of several cytokine genes clustered on the q-arm of chromosome 17. Chemokines are a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of N-terminal cysteine residues of the mature peptide. This chemokine is a member of the CC subfamily which is characterized by two adjacent cysteine residues. This cytokine displays chemotactic activity for monocytes and basophils but not for neutrophils or eosinophils. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis. It binds to chemokine receptors CCR2 and CCR4. Elevated expression of the encoded protein is associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. [provided by RefSeq, Aug 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.